Author Title Type [ Year(Desc)]
Filters: First Letter Of Title is V  [Clear All Filters]
Lu Y, Zhao Y, Liu P, Xu X. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal. Endocr Relat Cancer. 2023.
Sartor C, Brunetti L, Audisio E, Cignetti A, Zannoni L, Cristiano G, Nanni J, Ciruolo R, Zingarelli F, Ottaviani E, et al. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. Br J Haematol. 2023.
Goker H, Çınar OErkin, Demiroglu H, Malkan UYavuz, Karakulak EAladağ, Buyukasik Y. Venetoclax and Azacitidine Treatment in Relapsed Acute Myeloid Leukemia After Hematopoietic Stem Cell Transplantation: A Cohort Study in a Tertiary Center Real-World Setting. Turk J Haematol. 2023.
Pariury H, Fandel J, Bachl S, Ang KK, Markossian S, Wilson CG, Braun BS, Popescu B, Wohlfeil M, Beckman K, et al. Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia. Haematologica. 2023.
Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2023.
Liu Y, Li Y, Zhang R, Yu Z, Jing Y. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. Front Immunol. 2023;14:1269163.
Shah AMitesh, Pereira D, Poveda J, Wang TPeng. Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm. Leuk Res Rep. 2023;20:100380.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, et al. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023.
Zhao Y, Jiang S, Tang Y, Zhao L. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol. 2023.
Mekni S, Kanoun RYosra, Ladeb S, Belloumi D, Ben Abdeljelil N, Ben Othman T. Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report. Blood Res. 2023.
Szita VRéka, Wiedemann Á, Syoreni S, Tóth A, Ruff E, Gaál L, Masszi T, Varga G. [Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy]. Orv Hetil. 2023;164(23):894-899.
Kristensen DTuyet, Brøndum RFroberg, Ørskov ADue, Marcher CWerenberg, Schöllkopf C, Sørensen ALouise Tø, Severinsen MTang, Bøgsted M, Roug AStidsholt. Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy. Eur J Haematol. 2023.
Gong X, Zhang Y, He X, Moloudizargari M, Yu T, Wang L, Liu W, Jin L, Xu H, Xu Y, et al. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.
Ravindra A, Acharya L, Loeffler B, Mott S, Sutamtewagul G, Dhakal P. Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia. Leuk Res. 2023;135:107407.
Murthy GSubramania, Atallah E. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. Hematol Oncol Stem Cell Ther. 2023;16(4):346-350.
V JFHowick, Rezkalla JA, Tilbury T, Mankad SV, Bennett CE, Herrmann J, Barsness G, Ansell SM, Read MD. Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care Pathways. J Am Coll Cardiol. 2023.
Chiu J, Lazo-Langner A. Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review. Thromb Res. 2023;226:141-149.
Lopez-Virgen V, Gonzalez-Morales O, Gonzalez-Perez O. The ventricular-subventricular, subgranular and subcallosal zones: three niches of neural stem cells in the postnatal brain. Exp Brain Res. 2023.
Ishibashi Y, Nagafuku N, Kinoshita K, Okamura A, Shirakawa T, Suzuki I. Verification of the seizure liability of compounds based on their in vitro functional activity in cultured rat cortical neurons and co-cultured human iPSC-derived neurons with astrocytes and in vivo extrapolation to cerebrospinal fluid concentration. Toxicol Appl Pharmacol. 2023:116675.
Oh M-S, Lee S-G, Lee G-H, Kim C-Y, Song JHan, Yu B-Y, Chung HMin. Verification of therapeutic effect through Accelerator Mass Spectrometry based single cell level quantification of hESC-endothelial cells distributed into an ischemic model. Adv Healthc Mater. 2023:e2300476.
Wang S, Wu S, Yang Y, Zhang J, Wang Y, Zhang R, Yang L. Versatile Hydrogel Dressings that Dynamically Regulate The Healing of Infected Deep Burn Wounds. Adv Healthc Mater. 2023:e2301224.
Barone F, Amaral J, Bunea I, Farnoodian M, Gupta R, Gupta R, Baker D, M Phillips J, Blanch RJ, Maminishkis A, et al. A versatile laser-induced porcine model of outer retinal and choroidal degeneration for preclinical testing. JCI Insight. 2023;8(11).
Ochi H, Kato T, Zorn A, Hayashi T, Inoue T, Kondo M, Taira M, Michiue T. Versatile utilities of amphibians (part 5). Dev Growth Differ. 2023;65(8):459-460.
Feng J, Li Y, Li Y, Yin Q, Li H, Li J, Zhou B, Meng J, Lian H, Wu M, et al. Versican Promotes Cardiomyocyte Proliferation and Cardiac Repair. Circulation. 2023.
Anon. Vertebral Metastatic Tropism Is Driven by Vertebral Skeletal Stem Cells. Cancer Discov. 2023:OF1.